Macleods Pharma in South Africa

Macleods Pharmaceuticals Expands Footprint in South Africa’s Healthcare Sector

Johannesburg, South Africa – July 25, 2025

Macleods Pharmaceuticals, a leading Indian pharmaceutical company, has significantly bolstered its presence in South Africa, aiming to provide high-quality, affordable, and innovative therapeutic solutions to meet the diverse medical needs of the local population.

Strategic Expansion and Product Launches

Since mid-2022, Macleods has made substantial investments in South Africa, establishing a dedicated team of sales, marketing, and financial experts to complement its existing regulatory and logistics specialists. Under the leadership of CEO Jacques van Staden, the company has successfully launched 41 products since November 2024, with plans to introduce an additional 52 products by the end of June 2025. Notably, the launch of ziprasidone, a first-to-market generic, underscores Macleods’ commitment to delivering innovative and accessible healthcare solutions. (axesshealth.org)

Strategic Partnerships

To further enhance its growth strategy, Macleods has entered into a strategic commercial arrangement with Abex Pharmaceutica. This partnership grants Macleods access to a significant range of products that are highly synergistic to its existing portfolio. The majority of these products are in advanced stages of registration, ensuring a robust pipeline of over 70 products set to launch in the next 12 to 18 months. Additionally, Macleods has secured exclusive access to a pipeline of more than 100 new dossiers through EDGE Pharmaceuticals Limited, including options to introduce new innovations, biosimilars, and value-added niche products to the South African market. (axesshealth.org)

Commitment to Affordable Healthcare

Macleods’ dedication to providing affordable healthcare is evident in its reintroduction of rivastigmine, a medication aimed at improving the quality of life for patients with Alzheimer’s disease. This initiative reflects the company’s commitment to addressing critical health challenges in South Africa. (axesshealth.org)

Regulatory Approvals and Collaborations

In June 2022, Macleods received approval from the South African Health Products Regulatory Authority (SAHPRA) for its dolutegravir tablets, a treatment for children with HIV. This approval is part of Macleods’ ongoing efforts to support South Africa’s extensive HIV treatment program, which serves a significant portion of the global HIV-positive population. (medicaldialogues.in)

Furthermore, Macleods has been involved in discussions with South African authorities to establish a state-owned company focused on manufacturing antiretroviral (ARV) drugs locally. This initiative aims to strengthen the supply chain and ensure the sustainability of the world’s largest ARV treatment program. (sabcnews.com)

Conclusion

Macleods Pharmaceuticals’ strategic investments, partnerships, and product approvals underscore its commitment to enhancing healthcare accessibility and affordability in South Africa. Through these initiatives, the company continues to play a pivotal role in addressing the country’s pressing health challenges, particularly in the areas of HIV and Alzheimer’s disease treatment.

Macleods Pharmaceuticals’ Recent Developments in South Africa:

• Macleods – challenging the status quo in SA pharma
• Cipla, Macleods HIV child treatments approved in South Africa
• South Africa in talks with India’s Macleods to set up HIV drugs manufacturer locally – SABC News – Breaking news, special reports, world, business, sport coverage of all South African current events. Africa’s news leader.